Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 3
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME, Santegoets SJ, Welters MJP, de Bruin L, Visser M, van der Minne CE, de Kok PM, Loof NM, Boekestijn S, Roozen I, Westra IM, Meij P, Van der Burg SH, Kroep JR. Verdegaal EME, et al. Among authors: boekestijn s. J Immunother Cancer. 2023 Nov;11(11):e007697. doi: 10.1136/jitc-2023-007697. J Immunother Cancer. 2023. PMID: 37949617 Free PMC article.
Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of High-Grade Anal Intraepithelial Neoplasia in HIV+ Men.
Gosens KCM, van der Burg SH, Welters MJP, Boekestijn S, Loof NM, Quint WGV, van Noesel CJM, van der Wal AC, Richel O, Krebber WJTA, Melief CJM, de Vries HJC, Prins JM. Gosens KCM, et al. Among authors: boekestijn s. Clin Cancer Res. 2023 Oct 13;29(20):4109-4117. doi: 10.1158/1078-0432.CCR-22-3361. Clin Cancer Res. 2023. PMID: 37540563
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. Among authors: boekestijn s. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial.
Continuous Light Does Not Affect Atherosclerosis in APOE*3-Leiden.CETP Mice.
Schilperoort M, van den Berg R, Coomans CP, Khedoe PPSJ, Ramkisoensing A, Boekestijn S, Wang Y, Berbée JFP, Meijer JH, Biermasz NR, Rensen PCN, Kooijman S. Schilperoort M, et al. Among authors: boekestijn s. J Biol Rhythms. 2020 Dec;35(6):598-611. doi: 10.1177/0748730420951320. Epub 2020 Sep 11. J Biol Rhythms. 2020. PMID: 32915671 Free PMC article.
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH. Melief CJM, et al. Among authors: boekestijn s. Sci Transl Med. 2020 Mar 18;12(535):eaaz8235. doi: 10.1126/scitranslmed.aaz8235. Sci Transl Med. 2020. PMID: 32188726 Free article.
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors.
Duurland CL, Santegoets SJ, Abdulrahman Z, Loof NM, Sturm G, Wesselink TH, Arens R, Boekestijn S, Ehsan I, van Poelgeest MIE, Finotello F, Hackl H, Trajanoski Z, Ten Dijke P, Braud VM, Welters MJP, van der Burg SH. Duurland CL, et al. Among authors: boekestijn s. J Immunother Cancer. 2022 Jan;10(1):e003995. doi: 10.1136/jitc-2021-003995. J Immunother Cancer. 2022. PMID: 35039463 Free PMC article.
Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers.
Otterhaug T, Janetzki S, Welters MJP, Håkerud M, Nedberg AG, Edwards VT, Boekestijn S, Loof NM, Selbo PK, Olivecrona H, van der Burg SH, Høgset A. Otterhaug T, et al. Among authors: boekestijn s. Front Immunol. 2021 Jan 8;11:576756. doi: 10.3389/fimmu.2020.576756. eCollection 2020. Front Immunol. 2021. PMID: 33488576 Free PMC article. Clinical Trial.